BCT vs. APS, RVX, ATE, MBX, HBP, AEZS, TH, SVA, ONC, and LABS
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Aptose Biosciences (APS), Resverlogix (RVX), Antibe Therapeutics (ATE), Microbix Biosystems (MBX), Helix BioPharma (HBP), Aeterna Zentaris (AEZS), Theratechnologies (TH), Sernova (SVA), Oncolytics Biotech (ONC), and MediPharm Labs (LABS). These companies are all part of the "medical" sector.
BriaCell Therapeutics (TSE:BCT) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.
BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Aptose Biosciences received 211 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 72.11% of users gave Aptose Biosciences an outperform vote.
13.9% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of Aptose Biosciences shares are owned by institutional investors. 12.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
BriaCell Therapeutics' return on equity of -206.01% beat Aptose Biosciences' return on equity.
In the previous week, Aptose Biosciences had 8 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 8 mentions for Aptose Biosciences and 0 mentions for BriaCell Therapeutics. Aptose Biosciences' average media sentiment score of 0.23 beat BriaCell Therapeutics' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media.
Summary
BriaCell Therapeutics beats Aptose Biosciences on 8 of the 13 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
